

	MARICO STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR	D LIMITED THE OUARTEE	AND NINE M	ONTHS ENDER	DECEMBER	31 2024		
					DECEMBER	, 2021	Rs. in crore	
		Quarter ended				Nine months ended		
Sr. No.	Particulars	December 31, 2024 (Un-audited)	September 30, 2024 (Un-audited)	December 31, 2023 (Un-audited)	December 31, 2024 (Un-audited)	December 31, 2023 (Un-audited)	March 31, 2024 (Audited)	
1	Revenue from operations	2,794	2,664	2,422	8,101	7,375	9,653	
2	Other income	42	82	43	161	127	142	
3	Total Income (1 + 2)	2,836	2,746	2,465	8,262	7,502	9,795	
4	Expenses							
	(a) Cost of materials consumed	1,283	1,149	908	3,539	3,003	3,941	
	(b) Purchase of stock-in-trade	245 (117)	256	232 40	708	633	752 55	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (d) Employee benefits expense	207	(94) 213	189	(263) 623	557	743	
	(e) Finance cost	13	11	19	41	56	73	
	(f) Depreciation and amortisation expense	44	41	42	126	117	158	
	(g) Other expenses							
	Advertisement and sales promotion	293	290	246	823	726	952	
	Others	350	328	294	990	863	1,184	
	Total expenses	2,318	2,194	1,970	6,587	5,964	7,858	
5	Profit before tax (3 - 4)	518	552	495	1,675	1,538	1,937	
6	Tax expense							
	Current tax	129	117	61	381	277	353	
	Deferred tax charge / (credit)	(17)	2	48	(19)	79	82	
7	Tax expense for the period	406	119	109 386	362	356	435 1,502	
	Net profit for the period (5 - 6)	406	433	380	1,313	1,182	1,502	
8	Other comprehensive income / (loss) A. (i) Items that will not be reclassified to profit or loss Remeasurements of post employment benefit obligations (ii) Income tax relating to items that will not be reclassified to profit or loss Remeasurements of post employment benefit obligations B. (i) Items that will be reclassified to profit or loss	-	(0)	(0)	(0) 0	1 (0)	2 (0)	
	Exchange differences on translation of foreign operations	(16)	17	5	(59)	(37)	(75)	
	Change in fair value of hedging instrument	(1)	0	0	(0)	(0)	(0)	
	(ii) Income tax relating to items that will be reclassified to profit or loss		(1)					
	Change in fair value of hedging instrument	0	(0)	(0)	0	0	0	
	Total other comprehensive income / (loss)	(17)	17	4	(59)	(37)	(73)	
9	Total comprehensive income for the period (7+8)	389	450	390	1,254	1,145	1,429	
10	Net profit attributable to: - Owners	399	423	383	1,286	1,163	1,481	
11	- Non-controlling interests Other comprehensive income / (loss) attributable to:	7	10	3	27	19	21	
10	- Owners - Non-controlling interests	(18)	17	4 0	(55) (4)	(36) (1)	(72) (1)	
12	Total comprehensive income attributable to: - Owners - Non-controlling interests	381	440 10	387	1,231 23	1,127	1,409 20	
13	Paid-up equity share capital (Face value of Re. 1/- per share)	129	129	129	129	129	129	
13	Other equity	129	129	129	129	129	3,703	
15	Earnings per share (of Re. 1 /- each) ( Not annualised)							
	(a) Basic (in Rs.)	3.08	3.26	2.97	9.94	9.00	11.46	
	(b) Diluted (in Rs.)	3.07	3.26	2.96	9.91	8.98	11.43	
	See accompanying notes to the financial results							

Marico Limited Repg Office: 7th Floor Srande Palladium 175, CST Road, Kalina Santacruz (2) Mumbia 400 (398, India Tel: 91-02) 8648 0440 Fax (31-02) 8648 0440 Fax (31-02) 2658 0159 www.marico.com

CIN: L15140MH1988PLC049208 Email: investor@marico.com



## Notes to the Marico Limited Consolidated financial results:

- The Consolidated unaudited financial results for the quarter and nine months ended December 31, 2024 ("the statement") were reviewed by the Audit Committee and approved by the Board of Directors of Marico Limited ("the Company") at their meeting held on January 31, 2025 and are available on the Company's website - <u>http://www.marico.com</u> and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com). These results have been subjected to limited review by the statutory auditors.
- 2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3. The Consolidated financial results for the quarter and nine months ended December 31, 2024, comprise results of Marico Limited, its subsidiaries and step-down subsidiaries in India, Bangladesh, UAE, Egypt, South Africa, Malaysia, Sri Lanka, and Vietnam. All the aforesaid entities are collectively called 'Marico'.
- 4. During the quarter ended September 30, 2024, the Company had acquired the remaining 40% stake in Apcos Naturals Private Limited ("Just Herbs") from its Founders/Directors and other shareholder. Upon acquisition, Just Herbs has become a wholly owned subsidiary of the Company.
- 5. During the quarter ended September 30, 2023, the Company had acquired 32.84% stake (equivalent to 32.75% on a fully diluted basis) and gained control of Satiya Nutraceuticals Private Limited ("Plix") with effect from July 26, 2023. Subsequently, during the quarter ended December 31, 2023, the Company had acquired the next tranche of 18.54% (including an additional stake of 2.01%) in Plix increasing its total stake to 51.38% (equivalent to 51.24% on a fully diluted basis). Results for the nine months ended December 31, 2023, include the impact of the above transaction with effect from July 26, 2023, and are not comparable with other periods reported in the statement.

Marico Limited Regd Office: Th Floor Grande Palladium 175, CST Road, Kalinia Santacruz (E) Mumbai 400 096, India Tel: (91-22) 6648 0480 Fax (91-22) 2650 0159

www.marico.com



6. In accordance with the Indian Accounting Standard - Ind AS 108, the Company has organized the business into two segments viz, India and International. Accordingly, the Company has reported its segmental results for these segments.

(Rs.	in	crores)	)
------	----	---------	---

	Quarter ended			Nine mor	Year ended	
	December 31, September 30, December 31,		December 31,	December 31,	March 31,	
	2024	2024	2023	2024	2023	2024
	(Un-audited)	(Un-audited)	(Un-audited)	(Un-audited)	(Un-audited)	(Audited)
Segment revenue (Sales and other operating income)						
India	2,101	1,979	1,793	6,042	5,452	7,132
International	693	685	629	2,059	1,923	2,521
Total Segment Revenue	2,794	2,664	2,422	8,101	7,375	9,653
Less : Inter segment revenue	-	-	-	-	-	-
Net Segment Revenue	2,794	2,664	2,422	8,101	7,375	9,653
Segment Results (Profit before tax and interest)						
India	392	392	380	1,228	1,184	1,523
International	180	175	156	552	487	634
Total Segment Results	572	567	536	1,780	1,671	2,157
Less :						
(i) Finance cost	13	11	19	41	56	73
(ii) Other un-allocable expenditure net of un-allocable	41	4	22	64	77	147
income	41	4	22	04	//	147
Profit Before Tax	518	552	495	1,675	1,538	1,937
Segment Assets						
India	4,245	4,121	3,720	4,245	3,720	3,557
International	1,966	2,000	2,101	1,966	2,101	2,088
Un-allocated	2,424	2,003	2,225	2,424	2,225	1,776
Total Assets	8,635	8,124	8,046	8,635	8,046	7,421
Segment Liabilities						
India	1,165	1,179	1,264	1,165	1,264	1,131
International	736	695	803	736	803	874
Un-allocated	1,352	1,294	1,348	1,352	1,348	1,247
Total Liabilities	3,253	3,168	3,414	3,253	3,414	3,252

7. The Board of Directors of Marico Limited declared an interim dividend of Rs 3.50 per equity share of Re. 1 each at its meeting held on January 31, 2025. The interim dividend will be payable to those shareholders, whose name appears in the Register of Members as on February 7, 2025, being the record date for this purpose.

Saugata Gupta

Digitally signed by Saugata Gupta Date: 2025.01.31 12:41:23 +05'30'

Saugata Gupta

Managing Director & CEO

Place : Mumbai

Date : January 31, 2025

VIJAY Digitally signed by VIJAY MATHUR MATHUR 13:01:15 +05'30'

Marico Limited Repd Office: 7th Floor Grande Palladium 175, CST Road, Kalina Santacruz (E) Mumbai 400.096, India Tel: (91-22) 6648 0480 Fax (91-22) 2650 0159

www.marico.com

CIN: L15140MH1988PLC049208 Email: investor@marico.com

## About Marico:

Marico (BSE: 531642, NSE: "MARICO") is one of India's leading consumer goods companies operating in global beauty and wellness categories. During FY23-24, Marico recorded a turnover of INR 96.5 billion (USD 1.2 billion) through its products sold in India and chosen markets in Asia and Africa.

Marico touches the lives of 1 out of every 3 Indians, through its portfolio of brands such as Parachute, Saffola, Hair & Care, Parachute Advansed, Nihar Naturals, Mediker, Pure Sense, Coco Soul, Revive, Set Wet, Livon, Beardo, Just Herbs, True Elements and Plix. The international consumer products portfolio contributes to about 26% of the Group's revenue, with brands like Parachute, Parachute Advansed, HairCode, Fiancée, Purité de Prôvence, Ôliv, Caivil, Hercules, Black Chic, Code 10, Ingwe, X-Men, Thuan Phat and Isoplus.

As part of Marico's Green Initiative, your Company wants to make its contribution to save the environment by sending its shareholders the Annual Report and other communication using the electronic medium. Therefore, Members holding shares in dematerialized form are requested to contact their respective Depository Participant to update their email address. Members holding shares in physical form can write to the RTA at <u>rnt.helpdesk@linkintime.co.in</u>.

Marico Limited Reg Office: 7th floor, Grande Palladium, 175, CST Road, Kalina, Santacruz (East), Mumbai 400 098 Tel: (91-22) 6648 0480



MARICO LIMITED									
	STATEMENT OF STANDALONE FINANCIAL RESULTS FOR	THE QUARTER	AND NINE MC	NTHS ENDED	DECEMBER 3	1, 2024			
	Rs. in crore Ouarter ended Nine months ended Year ended								
		Quarter ended Ni			Nine mor	Nine months ended			
Sr. No.	Particulars	December 31, 2024 (Un-audited)	September 30, 2024 (Un-audited)	December 31, 2023 (Un-audited)	December 31, 2024 (Un-audited)	December 31, 2023 (Un-audited)	March 31, 2024 (Audited)		
1	Revenue from operations	1,965	1,860	1,733	5,711	5,365	7,002		
2	Other income	122	302	35	442	107	135		
3	Total Income (1 + 2)	2,087	2,162	1,768	6,153	5,472	7,137		
4	Expenses								
	(a) Cost of materials consumed	1,116	998	795	3,078	2,610	3,431		
	(b) Purchase of stock-in-trade	110	114	99	312	304	313		
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(101)	(80)	40	(223)	11	61		
	(d) Employee benefits expense	122	132	113	381	342	463		
	(e) Finance cost	6	7	8	18	25	32		
	(f) Depreciation and amortisation expense	29	28	29	85	80	107		
	(g) Other expenses								
	Advertisement and sales promotion	113	117	113	336	371	485		
	Others	241	234	209	690	618	843		
	Total expenses	1,636	1,550	1,406	4,677	4,361	5,735		
5	Profit before tax (3 - 4)	451	612	362	1,476	1,111	1,402		
6	Tax expense				_,	-,	_,		
	Current tax	85	77	29	250	179	230		
	Deferred tax charge / (credit)	(10)	6	49	10	83	94		
	Tax expense for the period	75	83	78	260	262	324		
7	Net profit for the period (5 - 6)	376	529	284	1,216	849	1,078		
8	Other comprehensive income								
	A. (i) Items that will not be reclassified to profit or loss								
	Remeasurements of post employment benefit obligations (ii) Income tax relating to items that will not be reclassified to profit or loss	-	(0)	-	(0)	0	1		
	Remeasurements of post employment benefit obligations B. (i) Items that will be reclassified to profit or loss	-	0	-	0	(0)	(0)		
	(ii) Income tax relating to items that will be reclassified to profit or loss	(1)	0	0	(0)	(0)	(0)		
	Change in fair value of hedging instrument	0	(0)	(0)	0	0	0		
	Total other comprehensive income for the period	(0)	(0)	0	(0)	0	0		
9	Total comprehensive income for the period (7 + 8)	376	529	284	1,216	849	1,078		
10	Paid-up equity share capital (Face value of Re. 1/- per share)	129	129	129	129	129	129		
11	Other equity						3,468		
	Earnings per share (of Re 1 /- each) ( Not annualised)						,		
	(a) Basic (in Rs.)	2.90	4.10	2.20	9.40	6.57	8.34		
	(b) Diluted (in Rs.)	2.89	4.09	2.19	9.37	6.55	8.32		
	See accompanying notes to the financial results	-	-	-	-				

CIN: L15140MH1988PLC049208 Email: investor@marico.com



## Notes to the Marico Limited Standalone financial results:

- The Standalone unaudited financial results for the quarter and nine months ended December 31, 2024 ("the statement") were reviewed by the Audit Committee and approved by the Board of Directors of Marico Limited ("the Company") at their meeting held on January 31, 2025 and are available on the Company's website <u>http://www.marico.com</u> and on the websites of BSE (<u>www.bseindia.com</u>) and NSE (<u>www.nseindia.com</u>). These results have been subjected to limited review by the statutory auditors.
- 2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3. In accordance with the Indian Accounting Standard Ind AS 108, the Company has disclosed segment results in consolidated financial results.
- 4. During the quarter ended September 30, 2024, the Company had acquired the remaining 40% stake in Apcos Naturals Private Limited ("Just Herbs") from its Founders/Directors and other shareholder. Upon acquisition, Just Herbs has become a wholly owned subsidiary of the Company.
- 5. During the quarter ended September 30, 2023, the Company had acquired 32.84% stake (equivalent to 32.75% on a fully diluted basis) and gained control of Satiya Nutraceuticals Private Limited ("Plix") with effect from July 26, 2023. Subsequently, during the quarter ended December 31, 2023, the Company had acquired the next tranche of 18.54% (including an additional stake of 2.01%) in Plix increasing its total stake to 51.38% (equivalent to 51.24% on a fully diluted basis).
- 6. The Board of Directors of Marico Limited declared an interim dividend of Rs 3.50 per equity share of Re. 1 each at its meeting held on January 31, 2025. The interim dividend will be payable to those shareholders, whose name appears in the Register of Members as on February 7, 2025, being the record date for this purpose.

Saugata Gupta

Digitally signed by Saugata Gupta Date: 2025.01.31 12:40:42 +05'30'

Saugata Gupta

Managing Director & CEO

Place : Mumbai

Date : January 31, 2025



Marico Limited Regd Office: 7th Floor Grande Palladium 175, CST Road, Kalina Santacruz (E) Mumbai 400.038, India Tel: 91-22, 6548.0480 Fax: 91-22, 2660.0159 Fax: 91-22, 2660.0159